In a recent post on the IVI-sponsored Health Affairs featured blog series, Peter Bach, Zachary Helms, and Nancy Yu leverage public data to estimate both the premiums that companies earn and the amount they spend on research, challenging pharmaceutical companies' claims regarding R&D spending. Read the full article here. About the Health Affairs/IVI Featured Blog Series: Drugs [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series, the National Pharmaceutical Council's Robert Dubois (also member of IVI Strategic Advisory Panel) and Kimberly Westrich examine current value assessment models' readiness for use in healthcare decision-making. Applying NPC's 35 Guiding Practices, they conclude that all existing frameworks possess individual strengths and weaknesses, but [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series, Jonathan Darrow, Aaron Kesselheim, and Jessica Lasky-Su outline the goals and promise of the Precision Medicine Initiative and Cancer Moonshot. Although they also outline some of the key challenges and limitations, the authors recognize that there is a significant opportunity to translate the advances [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series, Robert Galvin and Troyen Brennan make the case for employers and pharmacy benefit managers to challenge drug manufacturers' pricing models as a means of keeping costs in check, particularly in regard to launch prices. They suggest a strategy in which employers and pharmacy benefit [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series, Deborah Mazer and Gregory Curfman focus on provisions of the 21st Century Cures Act that will impact the FDA's oversight of approved drugs and medical devices, including subtle changes to the approval procedures and a provision that permits-off label promotion of health care economic [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series, Anupam Jena and IVI Strategic Advisory Panel member, Sachin Kamal-Bahl, examine the spillover effects of healthcare for patients' families. These family spillover benefits, they argue, may be significant. For example, a parent of a blind child would likely be willing to pay far more [...]
In a post on the the IVI-sponsored Health Affairs blog series, Peter Neumann and co-author Elle Pope examine Section 3037 of the Cures Act and new FDA draft guidance, which indicate that drug companies will have expanded flexibility to communicate proactively with payers and formulary committees about the real-world impacts of their products. Read the [...]
In a recent post on the IVI-sponsored Health Affairs blog series, Karl Lauterbach, John McDonough, and Elizabeth Seely suggest that Germany's AMNOG (the Act to Reorganize Pharmaceuticals Market in the Statutory Health Insurance System or Arzneimittelmarktneuordnungsgesetz) model should be applied to U.S. drug pricing policy. Read the full article here. About the Health Affairs/IVI Featured Blog Series: [...]
In a recent post on the IVI-sponsored Health Affairs blog series, Rachel Dolan looks at resistance to specific policies that attempt to move towards value-based reimbursement. Despite widespread bipartisan agreement that Medicare Part B should be paying for value, roadblocks are still formidable. Read the full article here. About the Health Affairs/IVI Featured Blog Series: Drugs [...]
In a recent post on the IVI-sponsored Health Affairs blog series, Ameet Sarpatwari and Michael Sinha discuss why the 21st Century Cures legislation increases risk of patient harm. Among the issues they highlight are uncertainty around funding -- especially for prevention, research, and regulatory science -- and the loosening of evidence standards for FDA approvals. [...]
